Illumina

Director, Health Economic Outcomes Research (Remote)

United States

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Genomics, Healthcare, DiagnosticsIndustries

Requirements

A Bachelor's degree is required, with an advanced degree (GC, MBA, MPH, PhD) being preferred. The role requires expertise in health economic outcomes research (HEOR) and market access strategies, particularly for molecular diagnostic solutions in oncology, genetic disease, and reproductive health. Experience in collaborating with global commercial, medical affairs, clinical development, and regional market access teams is necessary. The candidate must be a subject matter expert in translating data-driven evidence into clinical, economic, and societal value, with a strong understanding of quantitative research, health economic modeling, and publication strategies.

Responsibilities

The Director of HEOR will support global access strategies for molecular diagnostic solutions by designing, developing, and executing HEOR and Market Access projects, programs, and publications. This includes integrating HEOR and payer evidence into clinical trials and regulatory filings for US, EU, and Asian/Middle East/Emerging Markets. The role involves supporting global market access strategies, ensuring quantitative research and health economic modeling are undertaken, and advising on modeling and micro-costing capabilities. Responsibilities also include developing and executing a publication plan, securing reimbursement and access in key markets by addressing payer requirements and HTA processes, and monitoring global policy trends. The Director will build and maintain relationships with external stakeholders such as payers, HTA bodies, and advocacy groups, and provide strategic input into product development, launch planning, and lifecycle management, ensuring compliance with all relevant standards.

Skills

Health Economic Outcomes Research (HEOR)
Market Access
Genomic Technology
Molecular Diagnostics
Oncology
Genetic Disease
Reproductive Health
Clinical Trials
Regulatory Filings
Payer Evidence
Data Analysis
Value Demonstration

Illumina

Supports genomics startups through funding and resources

About Illumina

Illumina focuses on fostering innovation in the genomics industry by supporting startups through its Illumina Accelerator program. This program helps entrepreneurs create, launch, and grow genomics-focused companies by providing funding and resources. The accelerator operates in two main locations: the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator has successfully invested in 68 genomics startups, which have collectively raised over $1 billion in venture capital. What sets Illumina apart from its competitors is its strong partnership with leading venture capital investors and its dedicated focus on the genomics sector. The goal of Illumina is to build a thriving ecosystem for genomics innovation, enabling new companies to emerge and advance the field.

San Diego, CaliforniaHeadquarters
1998Year Founded
$27.2MTotal Funding
IPOCompany Stage
Venture Capital, BiotechnologyIndustries
5,001-10,000Employees

Risks

Over-reliance on NVIDIA's AI technology may limit flexibility in AI solution adoption.
Standardizing proteomics data across platforms could challenge Illumina's data reliability.
Single-flow-cell NovaSeq X System might cannibalize sales of higher-end models.

Differentiation

Illumina leads in genomic sequencing with advanced AI integration and multiomic data analysis.
The company offers innovative array-based solutions for DNA, RNA, and protein analysis.
Illumina's global expansion includes a new Global Capability Center in Bengaluru.

Upsides

Collaboration with NVIDIA enhances drug discovery and clinical development through AI integration.
Pilot proteomics program with UK Biobank aims to generate crucial reference datasets.
Single-cell sequencing kits make high-throughput sequencing accessible to smaller labs.

Land your dream remote job 3x faster with AI